Personalized diagnosis and treatment of hyperinsulinemic hypoglycaemia caused by beta-cell pathology

  • Description
  • Details
  • Subprojects
  • History
  • Relations
  • Publications
Project Title: Personalized diagnosis and treatment of hyperinsulinemic hypoglycaemia caused by beta-cell pathology
Project Number: CORDIS-185455
Project web address: Follow on CORDIS
Organization: Stichting Katholieke Universiteit, Netherlands, Nijmegen
Collaborators: University College London, GB
University Hospital Basel, CH
Ecole Polytechnique Federale De Lausanne, CH
University Of Bern, CH
Charité Universität Medicine, DE
Akademisch Ziekenhuis Groningen, NL
Paul Scherrer Institut, CH
Helsingin Yliopisto, FI
Turun Yliopisto, FI
Pichem Forschungs- Und Entwicklungsgmbh., AT
Universite De Lille Ii - Droit Et Sante, FR
Transmit Gesellschaft Fuer Technologietransfer Mbh, DE
Concentris Research Management Gmbh, DE
Exalos Ag, CH
Surgvision Bv, NL
Eanm Forschungs Gmbh, AT
Principal Investigators (PI): Theo Lasser, CH
Irene Walthert, CH
Eveline Fräßdorf, DE
Tiina Berg, FI
Michael Haberland, DE
Johanna M Van Apeldoorn, NL
Marie Gompel, FR
Ameli Schwalber, DE
Maarten Van Langen, NL
Mari Riipinen, FI
Kamila Kolasinska, GB
Marcus Duelk, CH
Thilo Wieczorek, CH
Birgit Schütz, AT
Emanuel Christ, CH
Ton Van Den Hoven, NL
Henrik Silber, AT
 
Project Description:
Background:Hyperinsulinaemic hypoglycaemia (HH) is a potentially lethal disease caused by over functioning beta cells derived from the pancreatic islets of Langerhans. Lethal HH and brain damage is a problem especially in infants with congenital HH. Current therapeutic approaches are associated with severe side effects/morbidity (diabetes, exocrine pancreas insufficiency etc.) considered acceptable in relation to the lethal outcome of HH although massively reducing quality of life and also life expectancy.Aims and objectives:In order to significantly improve therapy of this awful disorder, we propose to develop a simultaneous imaging/therapy platform allowing diagnostic imaging as well as image guided surgical, photodynamic or radiopeptide therapy to selectively resect/destroy diseased beta cells. This platform will enable delivery of patient-individual tailored therapy, increasing cure rate while significantly reducing or even avoiding side effects. The platform will integrate information from pre-clinical imaging for optimal therapy planning with intra-operative imaging for image guided surgery. By implementation of extended field optical coherence tomography, information on a histopathological level will allow increased precision of therapy. Highly innovative photodynamic therapy will enable selective (endoscopic) destruction of diseased beta cells without resection of pancreatic tissue.Outcome:Our highly-innovative integrated imaging/therapy (“theranostic”) platform will allow diagnosis and monitoring of disease, support and guide therapeutic intervention, predict outcome of intervention and individual prognosis. This technology will massively improve therapy, especially in infants, by improving cure rates while significantly reducing morbidity for improved quality of life and increased life expectancy. We will contribute to the goals of the International Rare Diseases Research Consortium (IRDiRC): 200 new therapies.
 
Project Terms:
life sciences
Project Title: Personalized diagnosis and treatment of hyperinsulinemic hypoglycaemia caused by beta-cell pathology
Project Number: CORDIS-185455
Project web address: Follow on CORDIS
Organization: Stichting Katholieke Universiteit, Netherlands, Nijmegen
Collaborators: University College London, GB
University Hospital Basel, CH
Ecole Polytechnique Federale De Lausanne, CH
University Of Bern, CH
Charité Universität Medicine, DE
Akademisch Ziekenhuis Groningen, NL
Paul Scherrer Institut, CH
Helsingin Yliopisto, FI
Turun Yliopisto, FI
Pichem Forschungs- Und Entwicklungsgmbh., AT
Universite De Lille Ii - Droit Et Sante, FR
Transmit Gesellschaft Fuer Technologietransfer Mbh, DE
Concentris Research Management Gmbh, DE
Exalos Ag, CH
Surgvision Bv, NL
Eanm Forschungs Gmbh, AT
Principal Investigators (PI): Theo Lasser, CH
Irene Walthert, CH
Eveline Fräßdorf, DE
Tiina Berg, FI
Michael Haberland, DE
Johanna M Van Apeldoorn, NL
Marie Gompel, FR
Ameli Schwalber, DE
Maarten Van Langen, NL
Mari Riipinen, FI
Kamila Kolasinska, GB
Marcus Duelk, CH
Thilo Wieczorek, CH
Birgit Schütz, AT
Emanuel Christ, CH
Ton Van Den Hoven, NL
Henrik Silber, AT
 
Project Categories:
Natural Sciences > Aging Diseases and Pathology
 
Other Information:
Fiscal Year: 2014
Project Start Date: 1 April 2014
Project End Date: 31 March 2018
Project program: FP7-HEALTH
 
Project Funding Information:
Funding Mechanism: CP-FP - Small or medium-scale focused research project
Year Funding Organization Total Funding, $
2014 European Research Council $8,628,376